Promising new treatment schedule for gefitinib responders after severe hepatotoxicity with daily administration [3]

Journal of Clinical Oncology

Volumn 24, Issue 19, 2006, Pages 3213-3214

  Seki, Nobuhiko ^a   Uematsu, Kazutsugu ^a   Shibakuki, Reishi ^a   Eguchi, Kenji ^a  

^a TOKAI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE;

AREA UNDER THE CURVE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG WITHDRAWAL; GENE MUTATION; HUMAN; LETTER; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; SIDE EFFECT; ADENOCARCINOMA; CASE REPORT; DRUG ADMINISTRATION; DRUG EFFECT; FEMALE; LIVER; LUNG TUMOR; MIDDLE AGED; NOTE; PHYSIOLOGY; TOXIC HEPATITIS;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEPATITIS, TOXIC; HUMANS; LIVER; LUNG NEOPLASMS; MIDDLE AGED; QUINAZOLINES;

EID: 34247362425     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.05.7109     Document Type: Letter

References (8)

1. Ho C, Davis J, Anderson F, et al: Side effects related to cancer treatment: CASE 1. Hepatitis following treatment with gefitinib. J Clin Oncol 23:8531-8533, 2005
2. Ranson M, Hammond LA, Ferry D, et al: ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: Results of a phase I trial. J Clin Oncol 20:2240-22450, 2002
3. Nakagawa K, Tamura T, Negoro S, et al: Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors. Ann Oncol 14:922-930, 2003
4. Baselga J, Rischin D, Ranson M, et al: Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 20:4292-4302, 2002
5. Herbst RS, Maddox AM, Rothenberg ML, et al: Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: Results of a phase I trial. J Clin Oncol 20:3815-3825, 2002
6. Fukuoka M, Yano S, Giaccone G, et al: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 21:2237-2246, 2003
7. Cappuzzo F, Hirsch FR, Rossi E, et al: Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97:643-655, 2005
8. Kris MG, Natale RB, Herbst RS, et al: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 290:2149-2158, 2003